Momenteel actieve connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
Qiaobing Xu | M | - |
Hopewell Therapeutics, Inc.
Hopewell Therapeutics, Inc. BiotechnologyHealth Technology Hopewell Therapeutics, Inc. is a company that is focused on discovering, synthesizing, and developing tissue-targeted lipid nanoparticles (TTLNPs) to bring genomic medicines to patients. The company is based in Woburn, MA and was founded in 2018 by Qiaobing Xu. Hopewell is pursuing opportunities to redefine the non-viral delivery space for novel genomic medicines by designing systemically administered LNPs to specifically target extrahepatic tissues and cells throughout the body. The company has built a robust intellectual property portfolio with an expansive library of ionizable lipids and has established partnerships with several industry-leading companies. Hopewell is developing its own internal pipeline, initially targeting diseases of the lung, while concurrently exploring the potential of its TTLNP platform for patients with unmet needs in oncology, infectious diseases, rare genetic diseases, and neurological disorders. Louis Brenner has been the CEO of the company since 2022. | 6 jaar |
Louis Brenner | M | 54 |
Hopewell Therapeutics, Inc.
Hopewell Therapeutics, Inc. BiotechnologyHealth Technology Hopewell Therapeutics, Inc. is a company that is focused on discovering, synthesizing, and developing tissue-targeted lipid nanoparticles (TTLNPs) to bring genomic medicines to patients. The company is based in Woburn, MA and was founded in 2018 by Qiaobing Xu. Hopewell is pursuing opportunities to redefine the non-viral delivery space for novel genomic medicines by designing systemically administered LNPs to specifically target extrahepatic tissues and cells throughout the body. The company has built a robust intellectual property portfolio with an expansive library of ionizable lipids and has established partnerships with several industry-leading companies. Hopewell is developing its own internal pipeline, initially targeting diseases of the lung, while concurrently exploring the potential of its TTLNP platform for patients with unmet needs in oncology, infectious diseases, rare genetic diseases, and neurological disorders. Louis Brenner has been the CEO of the company since 2022. | 2 jaar |
Howard Rosen | M | 66 |
Hopewell Therapeutics, Inc.
Hopewell Therapeutics, Inc. BiotechnologyHealth Technology Hopewell Therapeutics, Inc. is a company that is focused on discovering, synthesizing, and developing tissue-targeted lipid nanoparticles (TTLNPs) to bring genomic medicines to patients. The company is based in Woburn, MA and was founded in 2018 by Qiaobing Xu. Hopewell is pursuing opportunities to redefine the non-viral delivery space for novel genomic medicines by designing systemically administered LNPs to specifically target extrahepatic tissues and cells throughout the body. The company has built a robust intellectual property portfolio with an expansive library of ionizable lipids and has established partnerships with several industry-leading companies. Hopewell is developing its own internal pipeline, initially targeting diseases of the lung, while concurrently exploring the potential of its TTLNP platform for patients with unmet needs in oncology, infectious diseases, rare genetic diseases, and neurological disorders. Louis Brenner has been the CEO of the company since 2022. | - |
Thomas Hennessey | M | 76 |
Hopewell Therapeutics, Inc.
Hopewell Therapeutics, Inc. BiotechnologyHealth Technology Hopewell Therapeutics, Inc. is a company that is focused on discovering, synthesizing, and developing tissue-targeted lipid nanoparticles (TTLNPs) to bring genomic medicines to patients. The company is based in Woburn, MA and was founded in 2018 by Qiaobing Xu. Hopewell is pursuing opportunities to redefine the non-viral delivery space for novel genomic medicines by designing systemically administered LNPs to specifically target extrahepatic tissues and cells throughout the body. The company has built a robust intellectual property portfolio with an expansive library of ionizable lipids and has established partnerships with several industry-leading companies. Hopewell is developing its own internal pipeline, initially targeting diseases of the lung, while concurrently exploring the potential of its TTLNP platform for patients with unmet needs in oncology, infectious diseases, rare genetic diseases, and neurological disorders. Louis Brenner has been the CEO of the company since 2022. | - |
Ted Xutian Jing | M | - |
Hopewell Therapeutics, Inc.
Hopewell Therapeutics, Inc. BiotechnologyHealth Technology Hopewell Therapeutics, Inc. is a company that is focused on discovering, synthesizing, and developing tissue-targeted lipid nanoparticles (TTLNPs) to bring genomic medicines to patients. The company is based in Woburn, MA and was founded in 2018 by Qiaobing Xu. Hopewell is pursuing opportunities to redefine the non-viral delivery space for novel genomic medicines by designing systemically administered LNPs to specifically target extrahepatic tissues and cells throughout the body. The company has built a robust intellectual property portfolio with an expansive library of ionizable lipids and has established partnerships with several industry-leading companies. Hopewell is developing its own internal pipeline, initially targeting diseases of the lung, while concurrently exploring the potential of its TTLNP platform for patients with unmet needs in oncology, infectious diseases, rare genetic diseases, and neurological disorders. Louis Brenner has been the CEO of the company since 2022. | - |
Thomas Hennessey | M | - |
Hopewell Therapeutics, Inc.
Hopewell Therapeutics, Inc. BiotechnologyHealth Technology Hopewell Therapeutics, Inc. is a company that is focused on discovering, synthesizing, and developing tissue-targeted lipid nanoparticles (TTLNPs) to bring genomic medicines to patients. The company is based in Woburn, MA and was founded in 2018 by Qiaobing Xu. Hopewell is pursuing opportunities to redefine the non-viral delivery space for novel genomic medicines by designing systemically administered LNPs to specifically target extrahepatic tissues and cells throughout the body. The company has built a robust intellectual property portfolio with an expansive library of ionizable lipids and has established partnerships with several industry-leading companies. Hopewell is developing its own internal pipeline, initially targeting diseases of the lung, while concurrently exploring the potential of its TTLNP platform for patients with unmet needs in oncology, infectious diseases, rare genetic diseases, and neurological disorders. Louis Brenner has been the CEO of the company since 2022. | - |
Relatiegrafiek
Connectie in verschillende bedrijven
Statistieken
Land | Connecties | % van het totaal |
---|---|---|
Verenigde Staten | 6 | 100.00% |
Ouderdom van de connecties
Actief
Verleden
Man
Vrouw
Besturend
Uitvoerend
Oorsprong van de connecties